

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

(12) UK Patent Application (19) GB (11) 2 095 240 A

(21) Application No 8205929

(22) Date of filing 1 Mar 1982

(30) Priority data

(31) 8106902

(32) 5 Mar 1981

(33) United Kingdom (GB)

(43) Application published
29 Sep 1982

(51) INT CL³

C07D 403/12 A61K

31/505 C07D 239/36

(52) Domestic classification

C2C 1464 1510 1530

1601 215 220 226 22Y

246 247 248 250 251 252

254 258 25Y 280 281

28X 292 29Y 30Y 313

31Y 321 323 32Y 332 338

342 34Y 350 351 352 364

365 366 367 36Y 386 388

604 621 623 624 625 628

62X 634 661 662 678

699 761 762 802 80Y AA

KR KS MM TA TR

(56) Documents cited

None

(58) Field of search

C2C

(71) Applicant

Fujisawa Pharmaceutical

Co. Ltd.,

No. 3 Doshomachi,

4-chome,

Higashi-ku,

Osaka,

Japan

(72) Inventors

Tsutomu Teraji.

Teruo Oku,

Takayuki Namiki,

Norihiko Shimazaki

(74) Agents

Stevens, Hewlett and

Perkins,

5 Quality Court,


Chancery Lane,

London,

WC2A 1HZ

(54) Dihydropyrimidine derivatives,
processes for preparation thereof
and pharmaceutical composition
comprising the same

(57) Dihydropyrimidine derivatives
having the formula



wherein R¹ is pyridyl, thienyl or
optionally substituted aryl, and their
pharmaceutically-acceptable salts
have anti-allergic activity in human
beings and animals.

GB 2 095 240 A

SPECIFICATION

Dihydropyrimidine derivatives, processes for preparation thereof and pharmaceutical composition comprising the same


This invention relates to dihydropyrimidine derivatives. More particularly, it relates to
 5 dihydropyrimidine derivatives which have antiallergic activity, processes for the preparation thereof
 and a pharmaceutical composition comprising the same and to a method of use of the same in
 treatment of symptoms associated with allergic manifestations in human beings or animals.

Accordingly, it is an object of this invention to provide new dihydropyrimidine derivatives which
 are useful as an antiallergic agent.

10 Another object of this invention is to provide processes for preparing the dihydropyrimidine
 derivatives.

Further object of this invention is to provide a pharmaceutical composition comprising the
 dihydropyrimidine derivatives.

Dihydropyrimidine derivatives of this invention include the compound represented by the
 15 following formula:



wherein

R¹ is pyridyl, thienyl, or aryl which may bear one or more substituent(s) selected from the group of
 20 halogen, hydroxy, nitro, amino, di(lower)alkylamino, lower alkoxy and ar(lower)alkoxy, and
 pharmaceutically acceptable salts thereof.

Particulars of the above definitions and suitable examples thereof are explained as follows.

As to the term "lower" used in the specification and claims, it is to be understood that it means
 the one having 1 to 6 carbon atom(s), unless otherwise provided.

Suitable aryl for R¹ may be phenyl, tolyl, xylyl, naphthyl and the like.

25 Suitable halogen for the substituent of the aryl group may be fluorine, chlorine, bromine and
 iodine.



Suitable di(lower)alkylamino for the substituent of the aryl group may be dimethylamino,
 diethylamino, dipropylamino, diisopropylamino, methylethylamino, dibutylamino and the like.


30 Suitable lower alkoxy for the substituent of the aryl group may be methoxy, ethoxy, propoxy,
 isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy, hexyloxy and the like.

Suitable "ar(lower)alkoxy" for the substituent of the aryl group may be benzyloxy, phenethyloxy,
 benzhydryloxy, trityloxy and the like.

Suitable pharmaceutically acceptable salts of the compound (I) may be a salt with an inorganic or
 organic base (e.g. sodium salt, potassium salt, calcium salt, magnesium salt, trimethylamine salt,
 35 ethanolamine salt, etc.) and an acid addition salt (e.g. hydrochloride, sulfate, nitrate, maleate, acetate,
 etc.).

Dihydropyrimidine derivatives of this invention can be prepared by various processes as
 illustrated below.

Process 1:Process 2:

Process 3:

wherein

R¹ is the same as defined above,

5 R¹_a is aryl having a protected hydroxy group,



R¹_b is aryl having a hydroxy group,

R¹_c is aryl having a nitro group, and

R¹_d is aryl having an amino group.

Among the starting compounds (II), some novel compounds can be prepared by the following

10 Preparations (A) and (B) and the others can be prepared by a similar manner thereto.

Preparation (B)

wherein

15 R¹, R¹_c and R¹_d are each as defined above,

R¹_a is aryl having di(lower)alkylamino, and

R² is lower alkoxy.

The processes as illustrated above are explained in detail in the followings.

Process 1:

20 The object compound (I) or its salt can be prepared by reacting the compound (II) or its reactive derivative at the carboxy group with the compound (III) or its salt.

5

10

15

20

Suitable reactive derivatives of the compound (II) may be a conventional ones such as an acid halide, acid azide, an acid anhydride, an activated amide, an activated ester and the like.

Suitable salts of the compound (III) may be an acid addition salt (e.g. hydrochloride, etc.).

- When the starting compound (II) is used in a form of free acid, the reaction of this process may preferably be conducted in the presence of a condensing agent such as carbodiimidic compound (e.g. N,N'-carbonyldiimidazole, N,N'-dicyclohexylcarbodiimide, N-cyclohexyl-N'-morpholinoethylcarbodiimide, N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide, N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide, N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide, etc.), N,N'-carbonyldi-(2-methylimidazole), pentamethyleneketene-N-cyclohexylimine, diphenylketene-N-cyclohexylimine, alkoxyacetylene, 1-alkoxy-1-chloroethylene, trialkyl phosphite, ethyl polyphosphate, isopropyl polyphosphate, phosphorus compound (e.g. phosphorus oxychloride, phosphorus trichloride, etc.), thionyl chloride, oxalyl chloride, 2-ethyl-7-hydroxybenzisoxazolium salt, 2-ethyl-5-(m-sulfophenyl)isoxazolium hydroxide, (chloromethylene)-dimethylammonium chloride, 2,2,4,4,6,6-hexachloro-1,3,5,2,4,6-triazatriphosphorine, 1-benzenesulfonyloxy-6-chloro-1H-benzotriazole, p-toluenesulfonyl chloride, isopropoxybenzenesulfoxyl chloride, or a mixed condensing agent such as triphenylphosphine and a carbon tetrahalide (e.g. carbon tetrachloride, carbon tetrabromide, etc.) or a complex of N,N-dimethylformamide with phosphoryl chloride, phosgene or thionyl chloride, etc., and the like.

- The reaction is usually conducted in a solvent such as acetone, diethyl ether, dioxane, acetonitrile, ethyl acetate, N,N-dimethylformamide, dimethylsulfoxide, tetrahydrofuran, dichloromethane, chloroform, pyridine, N-methylmorpholine, N-methylpyrrolidine, etc. or a mixture thereof.

The reaction temperature is not critical and this reaction can be conducted within the temperature range of cooling to heating.

Process 2:

- The object compound (I_b) or its salt can be prepared by removing the protective group of the compound (I_a) or its salt.

The reaction conditions for removing the protective group may be selected according to the kind of the protective group. For instance, ar(lower)alkyl as a protective group can preferably be removed by catalytic reduction.

- The catalytic reduction is usually conducted at ambient temperature or under cooling in an inert solvent (e.g. N,N-dimethylformamide, ethanol, propanol, isobutyl alcohol, tetrahydrofuran, chloroform, ethyl acetate, acetic acid, etc.) by using a conventional catalyst such as Raney nickel, palladium on carbon, or the like.

Process 3:

- The compound (I_d) or its salt can be prepared by reducing the compound (I_c) or its salt. This reduction can also be carried out by a catalytic reduction. The conditions of the catalytic reduction are the same as explained in the above Process 2.

Preparation (A)

(1) Preparation of the compound (V)

- The compound (V) can be prepared by reacting the compound (VI) or its salt with the compound (VII).

Suitable lower alkoxy for R² of the starting compound (VII) is the same as exemplified before.

Suitable salts of the starting compound (VI) may be an inorganic or organic acid addition salt such as hydrochloride, sulfate, nitrate, trifluoroacetate, and the like.

- This reaction can be conducted in an inert solvent such as methanol, ethanol, propanol, N,N-dimethylformamide, dimethylsulfoxide and the like, under ice cooling—at ambient temperature.

(2) Preparation of compound (IV)

The compound (IV) can be prepared by hydrolyzing the compound (V).

- This hydrolysis can preferably be conducted in the presence of inorganic or organic acid such as hydrochloric acid, sulfuric acid, nitric acid, formic acid, acetic acid and the like.

The hydrolysis is usually conducted in an inert solvent such as water, acetone and the like, at ambient temperature—under heating.

(3) Preparation of the compound (II_a)

The compound (II_a) or its salt can be prepared by oxidizing the compound (IV).

- The oxidation can be carried out by using an oxidizing agent such as silver oxide, silver nitrate, potassium permanganate, and the like.

This oxidation can preferably be carried out in the presence of an inorganic or organic base (e.g. sodium hydroxide etc.)

- The reaction is usually carried out in an inert solvent such as methanol, tetrahydrofuran, water and the like at ambient temperature—under heating.

Preparation (B)**(1) Preparation of the compound (II_c)**

The compound (II_c) or its salt can be prepared by reducing the compound (II_b) or its salt.

This reduction can preferably be carried out by a catalytic reduction.

5 The conditions of the catalytic reduction are the same as those explained in the above Process 2. 5

(2) Preparation of the compound (II_d)

The compound (II_d) or its salt can be prepared by alkylating the compound (II_c) or its salt.

The alkylation can be carried out by reacting the compound (II_c) or its salt with

10 di(lower)alkylketone (e.g. acetone, etc.) or alkanal (e.g. formaldehyde, acetaldehyde, etc.) in the presence of a reducing agent such as a reducing agent containing boron in its molecule (e.g. sodium borohydride, sodium cyanoborohydride, etc.). 10

This reaction is usually carried out in an inert solvent such as water, methanol, ethanol, tetrahydrofuran and the like, at ambient temperature—under warming.

15 The object compound (I), (I_b) and (I_d) in the Process 1—3 can be isolated, purified and optionally converted into their salt in a conventional manner. 15

The object compound, dihydropyrimidine derivatives (I) have an antiallergic activity. Accordingly, the object compound of this invention is useful for the treatment of symptoms associated with allergic diseases such as allergic asthma, allergic rhinitis, urticaria, pollenosis, allergic conjunctivitis, atopic dermatitis, ulcerative colitis, alimentary allergy (e.g. milk allergy), bird fancier's disease, aphthous 20 stomatitis and the like. For illustrating purpose, the antiallergic activity of representative compound of the object compounds (I) shown in the followings. 20

Test I

[Inhibitory effect on PCA (Passive Cutaneous Anaphylaxis) reaction]

(1) Test compound

25 Sodium salt of 1,6-dihydro-6-oxo-2-(4-hydroxyphenyl)pyrimidine-4-[N-(5-tetrazolyl)]carboxamide. 25

(2) Test method**(a) Preparation of antiserum**

30 A solution of egg albumin (2 mg) in B pertussis-diphtheria-tetanus mixed vaccine (1 ml) was mixed with Freund incomplete adjuvant (1 ml) to give an emulsion. The emulsion was given subcutaneously in a single dose of 1 ml divided equally (0.25 ml) to the four foot pads of male SD (Sprague-Dawley) strain rats aged 8 weeks, each weighing about 300 g. 30

10 days after the immunization, blood samples were collected from femoral artery of the rats and allowed to stand under ice-cooling for 5 hours. The separated supernatant was centrifuged at 4°C 35 (10,000 r.p.m. × 1 hour). The antisera thus obtained were stored at -80°C prior to use. 35

(b) Inhibitory effect on P.C.A.

40 Male SD-strain rats aged 8 weeks, weighing 290 to 330 g, were used for PCA reaction with the homologous reaginic antiserum as prepared above. Each 0.1 ml of 32 fold diluted antiserum were injected intradermally at separate sites on the back of rats clipped free of hair, and 48 hours later, 1 ml of aqueous solution containing each 5 mg of the egg albumin and Evans blue was injected intravenously to evoke PCA reaction. Test compound was given to the animals intravenously 5 minutes before the challenge with antigen. Control group received vehicle. Each dose group consisted of 5 animals. One hour after the challenge with antigen, the animals were sacrificed and then skinned. Dye spots caused with antiserum were investigated for their size on the reversed side of the skin, 45 respectively. The results were expressed by per cent inhibition values calculated from averaged values of the longest and shortest diameters for each spot in comparison with those in control group. 45

(3) Test results

Test results are shown in the following table.

| <i>Dose of the Test Compound</i> | <i>Inhibitory effect (%)</i> |
|----------------------------------|------------------------------|
| 1 mg/kg | 100 |
| 0.1 mg/kg | 62.5 |

The dihydropyrimidine derivatives (I) of this invention can be used as an active antiallergic agent either in free form or in a form of the pharmaceutically acceptable salt.

The object compound (I) and its pharmaceutically acceptable salt can usually be administered to mammals including human beings in the form of a conventional pharmaceutical composition such as capsule, microcapsule, tablet, granule, powder, troche, syrup, aerosol, inhalation, solution, injection, suspension, emulsion, suppository, ointment, or the like.

The pharmaceutical composition of this invention can contain various organic or inorganic carrier materials, which are conventionally used for pharmaceutical purpose, such as excipient (e.g. sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate, etc.), binding agent (cellulose, methyl cellulose, hydroxypropylcellulose, polypropylpyrrolidone, gelatin, gum arabic, polyethyleneglycol, sucrose, starch, etc.), disintegrator (e.g. starch, carboxymethyl cellulose, calcium salt of carboxymethyl cellulose, hydroxypropylstarch, sodium glycole-starch, sodium bicarbonate, calcium phosphate, calcium citrate, etc.), lubricant (e.g. magnesium stearate, aerosil, talc, sodium laurylsulfate, etc.), flavoring agent (e.g. citric acid, mentol, ammonium salt of glycyrrhizine, glycine, orange powders, etc.), preservative (sodium benzoate, sodium bisulfite, methylparaben, propylparaben, etc.), stabilizer (citric acid, sodium citrate, acetic acid, etc.), suspending agent (e.g. methyl cellulose, polyvinylpyrrolidone, aluminum stearate, etc.), dispersing agent [e.g. polysorbate 80, emulgen 408 (surface active agent), emulsol (surface active agent), etc.], aqueous diluting agent (e.g. water), base wax (e.g. cacao butter, polyethyleneglycol, witopsol, white petrolatum, etc.).

A dosage of the present active ingredient is to be varied depending on various factors such as weight and/or age of a patient and/or a stage of the allergic disease, and further the kind of administration route. In general, an effective dosage may be in a range of about 20—2000 mg/day for an oral route, about 2.5—250 mg/day for an intramuscular or intravenous injection, about 10—1000 mg/day for a subcutaneous injection and about 120 mg—2000 mg/day for a rectal route. The total daily amount mentioned above may be divisionally given to the patient at the interval of 6—12 hours per day. Preferable single dose of the present active ingredient may be, for example, about 10—500 mg per tablet or capsule, about 1.25—250 mg per vial or ampoule, or about 60—500 mg per suppository, and so on, and further a pharmaceutical form for an external use may be, for example, about 1—10% ointment, solution or emulsion, etc.

The following Examples are given for the purpose of illustrating this invention.

Example 1

(1) To a solution of dry methanol (43 ml) containing sodium methoxide (prepared from 0.506 g of sodium metal) was added 4-benzyloxybenzamidinium methylsulfate (3.22 g.) under cooling in an ice bath and stirring. After stirring for 10 minutes, methyl γ,γ -dimethoxyacetoacetate (1.94 g.) was dropped over 2 minutes thereto. The mixture was stirred in an ice bath for 30 minutes and then at ambient temperature for 24 hours. The resulting mixture was adjusted to pH 4 with 10% hydrochloric acid and stirred in an ice bath for 10 minutes. The precipitates were collected by filtration, washed with water, and dried to give 3.23 g of 1,6-dihydro-6-oxo-2-(4-benzyloxyphenyl)pyrimidine-4-carbaldehyde dimethyl acetal. m.p. 194 to 196.5°C.

I.R. (nujol): 1660, 1605, 1595 cm^{-1}
N.M.R. (DMSO- d_6) δ ppm: 3.34 (s, 6H), 5.14 (s, 1H), 5.20 (s, 2H), 6.47 (s, 1H), 7.16 (d, J=9Hz, 2H), 7.44 (m, 5H), 8.17 (d, J=9Hz, 2H), 12.67 (bs, 1H)

(2) A mixture of 1,6-dihydro-6-oxo-2-(4-benzyloxyphenyl)-pyrimidine-4-carbaldehyde dimethyl acetal (14.14 g) and formic acid (58 ml) was stirred at ambient temperature for 30 minutes and then at 60 to 65°C for 2.5 hours. After cooling of the reaction mixture, the precipitates was filtered, washed with acetone and dried to give 11.92 g of 1,6-dihydro-6-oxo-2-(4-benzyloxyphenyl)-pyrimidine-4-carbaldehyde. m.p. 244 to 245°C.

I.R. (nujol) : 3150, 3075, 1715, 1645, 1600 cm^{-1}

(3) To a solution of 1,6-dihydro-6-oxo-2-(4-benzyloxyphenyl)pyrimidine-4-carbaldehyde (0.9 g) in 1/2N aqueous sodium hydroxide (12 ml) was added potassium permanganate (0.47 g) in the course of 10 minutes under cooling in an ice bath and stirring and the stirring was continued at ambient temperature for one hour, followed by filtration. The filtrate was washed five times with ethyl acetate, adjusted to pH 1 with 10% hydrochloric acid and allowed to stand for a while. The precipitates were filtered, washed with water and dried to give 0.80 g of 1,6-dihydro-6-oxo-2-(4-benzyloxyphenyl)pyrimidine-4-carboxylic acid. m.p. 253.5 to 254°C (dec.)

I.R. (nujol) : 2600, 2475, 2350, 1710, 1645 cm^{-1}

(4) To a suspension of 1,6-dihydro-6-oxo-2-(4-benzyloxyphenyl)pyrimidine-4-carboxylic acid (2.91 g) in N,N-dimethylformamide (29 ml) was added N,N'-carbonyldiimidazole (1.65 g) in one portion at ambient temperature. The mixture was stirred for 5 minutes at ambient temperature and for 35 minutes at 90°C, followed by addition of 5-aminotetrazole (1.08 g). The resulting mixture was stirred for an hour at 90°C and cooled slowly to ambient temperature. The precipitates were collected

by filtration, washed with ethanol and dried to give 3.36 g of 1,6-dihydro-6-oxo-2-(4-benzyloxyphenyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide. m.p. 298 to 301°C (dec.)

I.R. (nujol): 3225, 2675, 2575, 1685, 1675, 1600 cm^{-1}

N.M.R. ($\text{NaOD}+\text{D}_2\text{O}$) δ ppm: 5.20 (s, 2H), 6.74 (s, 1H), 6.90 (d, $J=9\text{Hz}$, 2H), 7.22 (s, 5H), 8.08 (d, $J=9\text{Hz}$, 2H)

5

Anal. Calcd. for $\text{C}_{19}\text{H}_{15}\text{N}_7\text{O}_3$: C; 58.61, H; 3.88, N; 25.18
found: C; 59.05, H; 5.94, N; 25.46

5

(5) A solution of 1,6-dihydro-6-oxo-2-(4-benzyloxyphenyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide (1.8 g) in water (54 ml) and 1N-aqueous sodium hydroxide (10 ml) containing 10% palladium on charcoal (0.6 g) was hydrogenated at 3.45 atmosphere hydrogen pressure.

10

10

After the calculated amount of hydrogen was absorbed, the catalyst was separated by filtration and washed with water. The combined filtrates were acidified with 10% hydrochloric acid. The precipitates were filtered, washed several times with water and purified by recrystallization from water (250 ml) containing sodium bicarbonate (1.70 g) to give 1.38 g of sodium salt of 1,6-dihydro-6-oxo-2-(4-hydroxyphenyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide. m.p. 300°C.

15

15

I.R. (nujol): 2600, 1660, 1595 cm^{-1}

N.M.R. ($\text{NaOD}+\text{D}_2\text{O}$) δ ppm: 6.78 (d, $J=9\text{Hz}$, 2H), 6.82 (s, 1H), 8.14 (d, $J=9\text{Hz}$, 2H)

Anal. Calcd. for $\text{C}_{12}\text{H}_8\text{O}_3\text{N}_7\text{Na}\cdot 3\text{H}_2\text{O}$: C; 38.41, H; 3.76, N; 26.13
found: C; 38.11, H; 3.96, N; 26.03

20 Example 2

20

(1) 1,6-Dihydro-6-oxo-2-phenylpyrimidine-4-carbaldehyde dimethyl acetal was obtained according to similar manner to that of Example 1 (1). m.p. 163 to 165°C (Recrystallization from ethyl acetate)

I.R. (nujol): 3150, 1660, 1605 cm^{-1}

25

Anal. Calcd. for $\text{C}_{13}\text{H}_{14}\text{O}_3\text{N}_2$: C; 63.40, H; 5.73, N; 11.38
found: C; 63.43, H; 5.82, N; 11.26

25

N.M.R. (CDCl_3) δ ppm: 3.48 (6H, s), 5.26 (1H, s), 6.75 (1H, s), 7.60—8.33 (5H, m)

(2) To a suspension of 1,6-dihydro-6-oxo-2-phenylpyrimidine-4-carbaldehyde dimethyl acetal (6.62 g) in acetone (60 ml) and dichloromethane (100 ml) was added conc. hydrochloric acid (14 ml) in one portion at ambient temperature. The mixture was stirred for 17 hours and concentrated to 20 ml, followed by the addition of water (50 ml). The aqueous layer was adjusted to pH 8 with an aqueous solution saturated with sodium bicarbonate. The separated solid was filtered, washed with water and dried under reduced pressure to give 3.88 g of 1,6-dihydro-6-oxo-2-phenylpyrimidine-4-carbaldehyde. m.p. 204 to 205°C.

30

30

I.R. (nujol): 3400, 1670, 1660, 1605 cm^{-1}

35

35

(3) To a suspension of 1,6-dihydro-6-oxo-2-phenylpyrimidine-4-carbaldehyde (6.0 g) in ethanol (100 ml) was added a solution of silver nitrate (7.74 g) in water (10 ml) at ambient temperature. After stirring for a few minutes, a solution of potassium hydroxide (5.6 g) in water (95 ml) was added dropwise over a interval of 15 minutes thereto. The reaction temperature was maintained below 30°C during the addition. The mixture was filtered to remove an insoluble materials, which were washed with water (50 ml). The filtrate was acidified with 10% hydrochloric acid and the precipitates were collected by filtration. This solid was dissolved in aqueous sodium bicarbonate and an insoluble materials were filtered off. The filtrate was acidified with 10% hydrochloric acid. The precipitates were collected by filtration, washed with water and dried to give 3.20 g of 1,6-dihydro-6-oxo-2-phenylpyrimidine-4-carboxylic acid. m.p. >270°C.

40

40

I.R. (nujol): 3050, 2500, 1700, 1650, 1600 cm^{-1}

45

45

(4) To a suspension of 1,6-dihydro-6-oxo-2-phenylpyrimidine-4-carboxylic acid (2.59 g) in N,N-dimethylformamide (26 ml) was added N,N'-carbonyldiimidazole (2.13 g) in one portion at ambient temperature. The mixture was stirred for 5 minutes at ambient temperature and then for 40 minutes at 90°C, followed by addition of 5-aminotetrazole (1.19 g). The resulting mixture was stirred for an hour at 90°C and cooled slowly to ambient temperature. The precipitates were collected by filtration and washed with water. After drying, the precipitates were recrystallized from water (140 ml) containing sodium bicarbonate (3.36 g) to yield 1.26 g of sodium salt of 1,6-dihydro-6-oxo-2-phenylpyrimidine-4-[N-(5-tetrazolyl)]-carboxamide. m.p. >270°C.

50

50

I.R. (nujol): 3250, 1700 (shoulder), 1650 cm^{-1}

55

55

Anal. Calcd. for $\text{C}_{12}\text{H}_8\text{N}_7\text{O}_2\text{Na}$: C; 47.22, H; 2.64, N; 32.12
found: C; 47.07, H; 2.79, N; 31.96

Example 3

(1) 1,6-Dihydro-6-oxo-2-(2-ethoxyphenyl)pyrimidine-4-carbaldehyde dimethyl acetal was obtained according to similar manner to that of Example 1 (1). m.p. 114 to 117°C.

I.R. (nujol): 3150, 1670, 1590 cm^{-1}

5 N.M.R. (CDCl_3) δ ppm: 1.63 (3H, t, $J=7\text{Hz}$), 3.48 (6H, s), 4.38 (2H, t, $J=7\text{Hz}$), 5.28 (1H, s), 6.68 (1H, s), 7.00—8.60 (4H, m), 11.50 (1H, bs) 5

Anal. Calcd. for $\text{C}_{15}\text{H}_{18}\text{N}_2\text{O}_4$: C; 62.05, H; 6.25, N; 9.65
found: C; 61.99, H; 6.03, N; 9.98

(2) 1,6-Dihydro-6-oxo-2-(2-ethoxyphenyl)pyrimidine-4-carbaldehyde was obtained according to similar manner to that of Example 2 (2). m.p. 167 to 170°C. 10
I.R. (nujol): 3250, 1710, 1665, 1580 cm^{-1}

(3) 1,6-Dihydro-6-oxo-2-(2-ethoxyphenyl)pyrimidine-4-carboxylic acid was obtained according to similar manner to that of Example 2 (3). m.p. >270°C.

I.R. (nujol): 3200, 2500, 1720, 1645 cm^{-1}

15 (4) 1,6-Dihydro-6-oxo-2-(2-ethoxyphenyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide was obtained according to similar manner to that of Example 1 (4). m.p. >270°C. 15

I.R. (nujol): 3350, 2500, 1700, 1660 cm^{-1}

Anal. Calcd. for $\text{C}_{14}\text{H}_{13}\text{N}_7\text{O}_3$: C; 51.37, H; 4.00, N; 29.96
found: C; 51.41, H; 3.71, N; 30.12

Example 4

(1) 1,6-Dihydro-6-oxo-2-(2-pyridyl)pyrimidine-4-carbaldehyde dimethyl acetal was obtained according to similar manner to that of Example 1 (1). m.p. 132°C. 20

I.R. (nujol): 3100, 1650, 1610 cm^{-1}

25 Anal. Calcd. for $\text{C}_{12}\text{H}_{13}\text{O}_3\text{N}_3$: C; 58.29, H; 5.30, N; 17.00
found: C; 58.33, H; 5.41, N; 17.03 25

N.M.R. (CDCl_3) δ ppm: 3.46 (6H, s), 5.20 (1H, s), 6.68 (1H, s), 7.33—8.76 (4H, m), 11.10 (1H, s)

(2) 1,6-Dihydro-6-oxo-2-(2-pyridyl)pyrimidine-4-carbaldehyde was obtained according to similar manner to that of Example 2 (2). m.p. 141 to 143°C.

I.R. (nujol): 3250, 1650, 1595 cm^{-1}

30 (3) 1,6-Dihydro-6-oxo-2-(2-pyridyl)pyrimidine-4-carboxylic acid was obtained according to similar manner to that of Example 1 (3). m.p. >270°C. 30
I.R. (nujol): 3350, 2500, 1735, 1675, 1595 cm^{-1}

(4) Sodium salt of 1,6-dihydro-6-oxo-2-(2-pyridyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide was obtained according to similar manner to that of Example 2 (4). m.p. >270°C. 35

35 I.R. (nujol): 3500, 3200, 1655, 1600 cm^{-1}

Anal. Calcd. for $\text{C}_{11}\text{H}_7\text{O}_2\text{N}_8\text{Na} \cdot 1/2 \text{H}_2\text{O}$: C; 41.91, H; 2.56, N; 35.54
found: C; 41.75, H; 2.86, N; 35.75

Example 5

(1) 1,6-Dihydro-6-oxo-2-(3-pyridyl)pyrimidine-4-carbaldehyde dimethyl acetal was obtained according to similar manner to that of Example 1 (1). m.p. 179 to 183°C. 40

I.R. (nujol): 2400, 1605, 1590 cm^{-1}

Anal. Calcd. for $\text{C}_{12}\text{H}_{13}\text{O}_3\text{N}_3$: C; 58.29, H; 5.30, N; 17.00
found: C; 58.30, H; 5.33, N; 16.89

N.M.R. ($\text{DMSO}-d_6$) δ ppm: 3.40 (6H, s), 5.22 (1H, s), 6.50 (1H, s), 7.58—9.31 (4H, m)

45 (2) 1,6-Dihydro-6-oxo-2-(3-pyridyl)pyrimidine-4-carbaldehyde was obtained according to similar manner to that of Example 2 (2). m.p. 168°C (dec.). 45
I.R. (nujol): 3200, 1715, 1670, 1600 cm^{-1}

(3) 1,6-Dihydro-6-oxo-2-(3-pyridyl)pyrimidine-4-carboxylic acid was obtained according to similar manner to that of Example 1 (3). m.p. >270°C.

50 I.R. (nujol): 2500, 1660, 1610 cm^{-1} 50

(4) Sodium salt of 1,6-dihydro-6-oxo-2-(3-pyridyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide was obtained according to similar manner to that of Example 2 (4). m.p. >270°C.

I.R. (nujol): 3250, 1680, 1610 cm^{-1}

(2) 1,6-Dihydro-6-oxo-2-(*o*-tolyl)pyrimidine-4-carbaldehyde was obtained according to similar manner to that of Example 2 (2). m.p. 203 to 205°C.
I.R. (nujol): 2800, 1700, 1650, 1605 cm⁻¹

(3) 1,6-Dihydro-6-oxo-2-(*o*-tolyl)pyrimidine-4-carboxylic acid was obtained according to similar manner to that of Example 2 (3). m.p. 250 to 252°C (dec.) (Recrystallization from aqueous 70% dimethylformamide).

I.R. (nujol): 2500, 1715, 1640, 1595 cm⁻¹

Anal. Calcd. for C₁₂H₁₀O₃N₂: C; 62.60, H; 4.38, N; 12.17
found: C; 62.48, H; 4.48, N; 12.16

10 Example 9

(1) 1,6-Dihydro-6-oxo-2-(4-chlorophenyl)pyrimidine-4-carbaldehyde dimethyl acetal was obtained according to similar manner to that of Example 1 (1). m.p. 223 to 227°C.

I.R. (nujol): 3050, 1655, 1595 cm⁻¹

N.M.R. (CDCl₃) δppm: 3.42 (6H, s), 5.20 (1H, s), 6.70 (1H, s), 7.51 (2H, d, J=8Hz), 8.25 (2H, d, J=8Hz)

Anal. Calcd for C₁₃H₁₃O₃N₂Cl: C; 55.62, H; 4.66, N; 9.98
Found: C; 55.38, H; 4.69, N; 9.91

(2) 1,6-Dihydro-6-oxo-2-(4-chlorophenyl)pyrimidine-4-carbaldehyde was obtained according to similar manner to that of Example 2 (2). m.p. 200 to 202°C.

I.R. (nujol): 1690, 1670 (shoulder), 1600 cm⁻¹

(3) 1,6-Dihydro-6-oxo-2-(4-chlorophenyl)pyrimidine-4-carboxylic acid was obtained according to similar manner to that of Example 2 (3). m.p. >270°C (recrystallization from dimethylformamide-diethylether)

I.R. (nujol): 3450, 1740 (shoulder), 1690, 1650, 1595 cm⁻¹

(4) 1,6-Dihydro-6-oxo-2-(4-chlorophenyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide was obtained according to similar manner to that of Example 1 (4). m.p. >270°C (Recrystallization from dimethylformamide)

I.R. (nujol): 3100, 1675, 1590 cm⁻¹

N.M.R. (D₂O+N₂OD) δppm: 6.76 (1H, s), 7.26 (2H, d, J=8Hz), 7.98 (2H, d, J=8Hz)

Anal. Calcd. for C₁₂H₁₈O₂N₇Cl·1/2 H₂O: C; 44.12, H; 2.77, N; 29.99
found: C; 44.20, H; 2.42, N; 29.97

Example 10

(1) 1,6-Dihydro-6-oxo-2-(4-nitrophenyl)pyrimidine-4-carbaldehyde dimethyl acetal was obtained according to similar manner to that of Example 1 (1). m.p. 259 to 260°C.

I.R. (nujol): 1650 cm⁻¹

N.M.R. (DMSO-d₆) δppm: 3.34 (6H, s), 5.22 (1H, s), 6.55 (1H, s), 8.35 (4H, s)

(2) 1,6-Dihydro-6-oxo-2-(4-nitrophenyl)pyrimidine-4-carbaldehyde was obtained according to similar manner to that of Example 2 (2). m.p. 287.5 to 288°C (dec.)

I.R. (nujol): 1710, 1650, 1610 cm⁻¹

(3) 1,6-Dihydro-6-oxo-2-(4-nitrophenyl)pyrimidine-4-carboxylic acid was obtained according to similar manner to that of Example 2 (3). m.p. 263 to 264°C.

I.R. (nujol): 3050, 2500, 1730 (shoulder), 1700, 1640, 1610 cm⁻¹

(4) 1,6-Dihydro-6-oxo-2-(4-nitrophenyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide was obtained according to similar manner to that of Example 1 (4). m.p. >300°C.

I.R. (nujol): 3625, 3450, 1670 cm⁻¹

(5) A solution of 1,6-dihydro-6-oxo-2-(4-nitrophenyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide (1.83 g) in water (73 ml) and sodium bicarbonate (1.41 g) containing 10% palladium on charcoal (0.74 g) was hydrogenated at 3.5 atmosphere. After the calculated amount of hydrogen was absorbed, the catalyst was separated by filtration and washed with water. The combined filtrates were acidified with 10% hydrochloric acid. The precipitates were collected by filtration, washed several times with water and purified by recrystallization from water (250 ml) containing sodium bicarbonate (2 g) to give 1.72 g of sodium salt of 1,6-dihydro-6-oxo-2-(4-aminophenyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide. m.p. >300°C.

I.R. (nujol): 3375, 3250, 3100, 1725, 1685, 1600 cm⁻¹

N.M.R. (D₂O+N₂OD) δppm: 6.55 (2H, d, J=9Hz), 6.63 (1H, s), 7.74 (2H, d, J=9Hz)

Anal. Calcd. for C₁₂H₉N₈O₂N₄·2H₂O: C; 40.42, H; 3.65, N; 31.46
found: C; 40.49, H; 3.41, N; 31.66

Example 11

(1) 1,6-Dihydro-6-oxo-2-(4-isopropoxyphenyl)pyrimidine-4-carbaldehyde dimethyl acetal was obtained according to similar manner to that of Example 1 (1). m.p. 161 to 162°C.

I.R. (nujol): 1660, 1605 cm^{-1}

5 N.M.R. (DMSO- d_6) δ ppm: 1.30 (6H, d, $J=6\text{Hz}$), 3.35 (6H, s), 4.74 (1H, m), 5.14 (1H, s), 6.30 (1H, s), 7.03 (2H, d, $J=9\text{Hz}$), 8.11 (2H, d, $J=9\text{Hz}$), 12.45 (1H, br s) 5

(2) 1,6-Dihydro-6-oxo-2-(4-isopropoxyphenyl)pyrimidine-4-carbaldehyde was obtained according to similar manner to that of Example 2 (2). m.p. 226 to 268°C (dec.) (Recrystallization from ethyl acetate)

10 I.R. (nujol): 3075, 1720, 1645, 1605 cm^{-1} 10

(3) 1,6-Dihydro-6-oxo-2-(4-isopropoxyphenyl)pyrimidine-4-carboxylic acid was obtained according to similar manner to that of Example 2 (3). m.p. 254 to 254.5°C (dec.) (recrystallization from dimethylformamide)

I.R. (nujol): 1755, 1640, 1600 cm^{-1}

15 Anal. Calcd. for $\text{C}_{14}\text{H}_{14}\text{N}_2\text{O}_4$: C; 61.31 H; 5.14, N; 10.21 15
Found: C; 61.34, H; 5.00, N; 10.29

(4) Sodium salt of 1,6-dihydro-6-oxo-2-(4-isopropoxyphenyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide was obtained according to similar manner to that of Example 2 (4). m.p. >300°C.

I.R. (nujol): 3300, 3075, 1715 (shoulder), 1685, 1605 cm^{-1}

20 N.M.R. (DMSO- d_6) δ ppm: 1.30 (6H, d, $J=6\text{Hz}$), 4.76 (1H, m), 6.94 (1H, s), 7.07 (2H, d, $J=9\text{Hz}$), 8.41 (2H, d, $J=9\text{Hz}$) 20

Anal. Calcd. for $\text{C}_{15}\text{H}_{14}\text{N}_7\text{O}_3\text{Na}\cdot\text{H}_2\text{O}$: C; 47.24, H; 4.19, N; 25.72
found: C; 46.56, H; 4.10, N; 26.13

Example 12

25 (1) 1,6-Dihydro-6-oxo-2-(m-tolyl)pyrimidine-4-carbaldehyde dimethyl acetal was obtained according to similar manner to that of Example 1 (1). m.p. 178 to 179°C. 25

I.R. (nujol): 1655, 1550 cm^{-1}

N.M.R. (DMSO- d_6) δ ppm: 2.40 (3H, s), 3.34 (6H, s), 5.17 (1H, s), 6.37 (1H, s), 7.43 (2H, m), 7.97 (2H, m), 12.67 (1H, br s)

30 (2) 1,6-Dihydro-6-oxo-2-(m-tolyl)pyrimidine-4-carbaldehyde was obtained according to similar manner to that of Example 2 (2). m.p. 215 to 225°C (dec.) (Recrystallization from methyl alcohol) 30

I.R. (nujol): 3275, 1670, 1600 cm^{-1}

(3) 1,6-Dihydro-6-oxo-2-(m-tolyl)pyrimidine-4-carboxylic acid was obtained according to similar manner to that of Example 2 (3). m.p. 258 to 258.5°C (dec.) (Recrystallization from dimethylformamide)

35 I.R. (nujol): 3075, 2575, 2450, 1705, 1635, 1570 cm^{-1} 35

Anal. Calcd. for $\text{C}_{12}\text{H}_{10}\text{N}_2\text{O}_3$: C; 62.61, H; 4.38, N; 12.17
found: C; 62.73, H; 4.29, N; 12.37

(4) 1,6-Dihydro-6-oxo-2-(m-tolyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide was obtained according to similar manner to that of 1 (4). m.p. >300°C.

40 I.R. (nujol): 3350, 3150, 1680, 1575 cm^{-1} 40

N.M.R. ($\text{D}_2\text{O}+\text{N}_4\text{HCO}_3$) δ ppm: 2.06 (3H, s), 6.58 (1H, s), 6.98 (2H, m), 7.58 (2H, m)

Anal. Calcd. for $\text{C}_{13}\text{H}_{11}\text{N}_7\text{O}_2\cdot 1/2\text{H}_2\text{O}$: C; 50.98, H; 3.94, N; 32.01
found: C; 51.28, H; 4.16, N; 32.47

Example 13

45 (1) 1,6-Dihydro-6-oxo-2-(2-thienyl)pyrimidine-4-carbaldehyde dimethyl acetal was obtained according to similar manner to that of Example 1 (1). m.p. 213 to 215°C (dec.) 45

I.R. (nujol): 3075, 1650 cm^{-1}

50 N.M.R. (DMSO- d_6) δ ppm: 3.40 (6H, s), 5.16 (1H, s), 6.36 (1H, s), 7.27—8.23 (3H, m), 12.74 (1H, br s) 50

(2) 1,6-Dihydro-6-oxo-2-(2-thienyl)pyrimidine-4-carbaldehyde was obtained according to similar manner to that of Example 2 (2). m.p. >300°C.

I.R. (nujol): 3300, 3075, 1680 cm^{-1}

55 (3) 1,6-Dihydro-6-oxo-2-(2-thienyl)pyrimidine-4-carboxylic acid was obtained according to similar manner to that of Example 2 (3). m.p. 254 to 254.5°C (dec.) (Recrystallization from dimethylformamide) 55

I.R. (nujol): 3080, 2600, 2450, 1730, 1675, 1640 cm^{-1}

(4) 1,6-Dihydro-6-oxo-2-(2-thienyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide was obtained according to similar manner to that of Example 1 (4). m.p. >300°C.

I.R. (nujol): 3300, 3075, 1700 (shoulder), 1680, 1650 (shoulder), 1580, 1555 cm⁻¹

N.M.R. (D₂O+N₈HCO₃) δppm: 6.52 (1H, s), 6.74—7.52 (3H, m)

5 Anal. Calcd. for C₁₀H₇N₇O₂S·1/4H₂O: C; 40.84, H; 2.55, N; 33.37
found: C; 40.94, H; 2.35, N; 33.13 5

Example 14

(1) 1,6-Dihydro-6-oxo-2-(p-tolyl)pyrimidine-4-carbaldehyde dimethyl acetal was obtained according to similar manner to that of Example 1 (1). m.p. 197 to 198°C (Recrystallization from ethyl 10 alcohol) 10

I.R. (nujol): 1650, 1595 cm⁻¹

N.M.R. (DMSO—d₆) δppm: 2.38 (3H, s), 3.32 (6H, s), 5.12 (1H, s), 6.32 (1H, s), 7.30 (2H, d, J=8Hz), 8.02 (2H, d, J=8Hz), 12.74 (1H, br s)

15 Anal. Calcd. for C₁₄H₁₈N₂O₃: C; 64.60, H; 6.20, N; 10.76
found: C; 65.05, H; 6.30, N; 10.74 15

(2) 1,6-Dihydro-6-oxo-2-(p-tolyl)pyrimidine-4-carbaldehyde was obtained according to similar manner to that of Example 2 (2). m.p. 207 to 244°C (dec.)
I.R. (nujol): 3375, 1715, 1655, 1610, 1590

(3) 1,6-Dihydro-6-oxo-2-(p-tolyl)pyrimidine-4-carboxylic acid was obtained according to similar 20 manner to that of Example 2 (3). m.p. 255.5 to 260°C (dec.) 20

I.R. (nujol): 1760, 1645, 1590 cm⁻¹

Anal. Calcd. for C₁₂H₁₀N₂O₃: C; 62.61, H; 4.38, N; 12.17
found: C; 62.20, H; 4.46, N; 12.20

(4) Sodium salt of 1,6-dihydro-6-oxo-2-(p-tolyl)-pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide was 25 obtained according to similar manner to that of Example 2 (4). m.p. >300°C. 25

I.R. (nujol): 3300, 3050, 1715, 1680, 1595 cm⁻¹

N.M.R. (DMSO—d₆) δppm: 2.38 (3H, s), 6.90 (1H, s), 7.34 (2H, d, J=8Hz), 8.30 (2H, d, J=8Hz)

Anal. Calcd. for C₁₃H₁₀N₇O₂N₈·2H₂O: C; 43.95, H; 3.97, N; 27.60
found: C; 43.45, H; 3.85, N; 27.41

30 Example 15 30

(1) 1,6-Dihydro-6-oxo-2-(4-methoxyphenyl)pyrimidine-4-carbaldehyde dimethyl acetal was obtained according to similar manner to that of Example 1 (1). m.p. 205 to 206°C (Recrystallization from ethanol)

I.R. (nujol): 1660, 1605 cm⁻¹

35 N.M.R. (DMSO—d₆) δppm: 3.32 (6H, s), 3.82 (3H, s), 5.10 (1H, s), 6.28 (1H, s), 7.06 (2H, d, J=9Hz), 8.10 (2H, d, J=9Hz), 12.68 (1H, br s) 35

Anal. Calcd. for C₁₄H₁₆N₂O₄: C; 60.86, H; 5.84, N; 10.14
found: C; 60.63, H; 5.92, N; 9.96

(2) 1,6-Dihydro-6-oxo-2-(4-methoxyphenyl)pyrimidine-4-carbaldehyde was obtained according 40 to similar manner to that of Example 2 (2). m.p. 229 to 232°C. (Recrystallization from dimethylformamide) 40

I.R. (nujol): 3075, 1710, 1665, 1605 cm⁻¹

(3) 1,6-Dihydro-6-oxo-2-(4-methoxyphenyl)pyrimidine-4-carboxylic acid was obtained according to similar manner to that of Example 2 (3). m.p. 249 to 250°C (dec.)

45 I.R. (nujol): 2575, 2475, 1705, 1645, 1610 cm⁻¹ 45

(4) 1,6-Dihydro-6-oxo-2-(4-methoxyphenyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide was obtained according to similar manner to that of Example 2 (4), m.p. >300°C.

I.R. (nujol): 3275, 3075, 1710, 1680, 1605, 1545 cm⁻¹

50 N.M.R. (D₂O+N₈OD) δppm: 3.85 (3H, s), 6.65 (1H, s), 7.07 (2H, d, J=9Hz), 8.10 (2H, d, J=9Hz)
Anal. Calcd. for C₁₃H₁₀N₇O₃N₈·2H₂O: C; 42.06, H; 3.80, N; 26.41
found: C; 42.27, H; 3.51, N; 26.94 50

Example 16

(1) A solution of 1,6-dihydro-6-oxo-2-(4-nitrophenyl)-pyrimidine-4-carboxylic acid (4 g) and sodium bicarbonate (3.84 g) in water (200 ml) containing 10% palladium on charcoal (2 g) was 55 hydrogenated at 3.4 atmosphere hydrogen pressure. After being agitated for 3 hours, the mixture was warmed and the catalyst was separated by filtration followed by washing with water. The filtrate was adjusted to pH 3 to 4 with 10% hydrochloric acid. The precipitates were collected, washed with water

and dried to give 1.76 g of 1,6-dihydro-6-oxo-2-(4-aminophenyl)pyrimidine-4-carboxylic acid. m.p. 264 to 267°C. (dec.)

I.R. (nujol): 3300, 2600, 1630 cm^{-1}

- (2) To a suspension of 1,6-dihydro-6-oxo-2-(4-aminophenyl)pyrimidine-4-carboxylic acid (2.0 g) in methanol (356 ml) was added acetic acid (71 ml) and 37% aqueous formaldehyde (7.13 ml) successively. After being stirred at room temperature for 15 minutes, sodium cyanoborohydride (1.65 g) was added in one portion. The resulting mixture was stirred at ambient temperature for 5 hours. The precipitates were collected, washed with methanol and water, and dried to yield 1.82 g of 1,6-dihydro-6-oxo-2-(4-dimethylaminophenyl)pyrimidine-4-carboxylic acid. m.p. 270°C (dec.)
- I.R. (nujol): 1750, 1635, 1600 cm^{-1}

- (3) Sodium salt of 1,6-dihydro-6-oxo-2-(4-dimethylaminophenyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide was obtained according to similar manner to that of Example 2 (4). m.p. >300°C.
- I.R. (nujol): 3600, 3325, 3075, 1690, 1650, 1610 cm^{-1}
- N.M.R. ($\text{D}_2\text{O} + \text{N}_3\text{OD}$) δ ppm: 2.70 (6H, s), 6.44 (2H, d, J=9Hz), 6.64 (1H, s), 7.79 (2H, d, J=9Hz)
- Anal. Calcd. for $\text{C}_{14}\text{H}_{13}\text{N}_8\text{O}_2\text{N}_3 \cdot \text{H}_2\text{O}$: C; 45.90, H; 4.12, N; 30.59
- found: C; 45.50, H; 3.97, N; 30.81

Example 17

- (1) 1,6-Dihydro-6-oxo-2-(4-methoxy-3-methylphenyl)-pyrimidine-4-carbaldehyde dimethyl acetal was obtained according to similar manner to that of Example 1 (1). m.p. 216 to 217°C.
- I.R. (nujol): 3150, 3050, 1655, 1610 cm^{-1}
- N.M.R. ($\text{DMSO}-d_6$) δ ppm: 2.20 (3H, s), 3.33 (6H, s), 3.87 (3H, s), 5.10 (1H, s), 6.24 (1H, s), 7.04 (1H, d, J=10Hz), 8.00 (2H, m), 12.45 (1H, br s)

- (2) 1,6-Dihydro-6-oxo-2-(4-methoxy-3-methylphenyl)pyrimidine-4-carbaldehyde was obtained according to similar manner to that of Example 2 (2). m.p. 258.5 to 259°C (dec.)
- I.R. (nujol): 3150, 3050, 1715, 1670, 1610 cm^{-1}

(3) 1,6-Dihydro-6-oxo-2-(4-methoxy-3-methylphenyl)pyrimidine-4-carboxylic acid was obtained according to similar manner to that of Example 1 (3). m.p. 264°C. (dec.)

I.R. (nujol): 3050, 1700, 1640, 1605 cm^{-1}

- (4) 1,6-Dihydro-6-oxo-2-(4-methoxy-3-methylphenyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide was obtained according to similar manner to that of Example 1 (4). m.p. >300°C.
- I.R. (nujol): 3475, 3150, 1675, 1610 (shoulder) cm^{-1}
- N.M.R. ($\text{D}_2\text{O} + \text{N}_3\text{OD}$) δ ppm: 1.90 (3H, s), 3.58 (3H, s), 6.51 (1H, d, J=10Hz), 6.58 (1H, s), 7.65 (2H, m)
- Anal. Calcd. for $\text{C}_{14}\text{H}_{13}\text{N}_7\text{O}_3 \cdot 1/2\text{H}_2\text{O}$: C; 49.95, H; 4.16, N; 29.10
- found: C; 49.65, H; 4.15, N; 28.97

Example 18

- (1) 1,6-Dihydro-6-oxo-2-(4-ethoxyphenyl)pyrimidine-4-carbaldehyde dimethyl acetal was obtained according to similar manner to that of Example 1 (1). m.p. 198 to 199°C.
- I.R. (nujol): 3150, 1660, 1610, 1595 cm^{-1}
- N.M.R. ($\text{DMSO}-d_6$) δ ppm: 1.35 (3H, t, J=7Hz), 3.34 (6H, s), 4.15 (2H, q, J=7Hz), 5.14 (1H, s), 6.30 (1H, s), 7.08 (2H, d, J=9Hz), 8.15 (8H, d, J=9Hz), 12.67 (1H, br s)

(2) 1,6-Dihydro-6-oxo-2-(4-ethoxyphenyl)pyrimidine-4-carbaldehyde was obtained according to similar manner to that of Example 2 (2). m.p. 239 to 240°C.

I.R. (nujol): 1710, 1680, 1605 cm^{-1}

- (3) 1,6-Dihydro-6-oxo-2-(4-ethoxyphenyl)pyrimidine-4-carboxylic acid was obtained according to similar manner to that of Example 1 (3). m.p. 238 to 239°C. (dec.)
- I.R. (nujol): 3075, 2600, 2475, 1710, 1645, 1610 cm^{-1}

- (4) Sodium salt of 1,6-dihydro-6-oxo-2-(4-ethoxyphenyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide was obtained according to similar manner to that of Example 2 (4). m.p. >300°C.
- I.R. (nujol): 3375, 1705, 1610, 1550 cm^{-1}
- N.M.R. ($\text{D}_2\text{O} + \text{N}_3\text{OD}$) δ ppm: 1.34 (3H, t, J=7Hz), 4.06 (2H, q, J=7Hz), 6.74 (1H, s), 7.00 (2H, d, J=9Hz), 8.08 (2H, d, J=9Hz)
- Anal. Calcd. for $\text{C}_{14}\text{H}_{12}\text{N}_7\text{O}_3\text{N}_3 \cdot \text{H}_2\text{O}$: C; 45.74, H; 3.81, N; 26.68
- Found: C; 45.13, H; 3.79, N; 26.81

Example 19

(1) 1,6-Dihydro-6-oxo-2-(4-butoxyphenyl)pyrimidine-4-carbaldehyde dimethyl acetal was obtained according to similar manner to that of Example 1 (1). m.p. 158 to 159°C.

I.R. (nujol): 3125, 3050, 1655, 1605 cm^{-1}

5 N.M.R. (CDCl_3) δ ppm: 1.00 (3H, m), 1.67 (4H, m) 3.42 (6H, s), 4.03 (2H, t, J=6Hz), 5.17 (1H, s), 6.62 (1H, s), 6.98 (2H, d, J=9Hz), 8.22 (2H, d, J=9Hz), 12.78 (1H, br s)

(2) 1,6-Dihydro-6-oxo-2-(4-butoxyphenyl)pyrimidine-4-carbaldehyde was obtained according to similar manner to that of Example 2 (1). m.p. 215 to 216°C.

I.R. (nujol): 3150, 3075, 1705, 1655, 1605 cm^{-1}

10 (3) 1,6-Dihydro-6-oxo-2-(4-butoxyphenyl)pyrimidine-4-carboxylic acid was obtained according to similar manner to that of Example 1 (3). m.p. 246°C. (dec.) (Recrystallization from dimethylformamide)

I.R. (nujol): 2580, 2475, 1710, 1645, 1610 cm^{-1}

15 (4) Sodium salt of 1,6-dihydro-6-oxo-2-(4-butoxyphenyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide was obtained according to similar manner to that of Example 2 (4). m.p. >300°C.

I.R. (nujol): 3325, 3075, 1720, 1690, 1605 cm^{-1}

N.M.R. ($\text{N}_2\text{OD}+\text{D}_2\text{O}$) δ ppm: 0.84 (3H, t, J=7Hz), 1.00—1.80 (4H, m), 3.72 (2H, t, J=6Hz), 6.78 (2H, d, J=9Hz), 6.82 (1H, s), 8.06 (2H, d, J=9Hz)

20 Anal. Calcd. for $\text{C}_{16}\text{H}_{16}\text{N}_7\text{O}_3\text{Na}\cdot\text{H}_2\text{O}$: C; 48.61, H; 4.59, N; 24.80
found: C; 48.44, H; 4.61, N; 24.92

Example 20

(1) 1,6-Dihydro-6-oxo-2-(4-propoxyphenyl)pyrimidine-4-carbaldehyde dimethyl acetal was obtained according to similar manner to that of Example 1 (1). m.p. 167 to 168°C.

I.R. (nujol): 3150, 3075, 1670, 1655 (shoulder), 1605 1595 cm^{-1}

25 N.M.R. ($\text{DMSO}-d_6$) δ ppm: 1.00 (3H, t, J=7Hz), 1.77 (2H, m), 3.35 (6H, s), 4.02 (2H, t, J=7Hz), 5.13 (1H, s), 6.30 (1H, s), 7.05 (2H, d, J=9Hz), 8.13 (2H, d, J=9Hz)

(2) 1,6-Dihydro-6-oxo-2-(4-propoxyphenyl)pyrimidine-4-carbaldehyde was obtained according to similar manner to that of Example 2 (2). m.p. 198 to 199°C.

I.R. (nujol): 3150, 3075, 1710, 1655, 1605 cm^{-1}

30 (3) 1,6-Dihydro-6-oxo-2-(4-propoxyphenyl)pyrimidine-4-carboxylic acid was obtained according to similar manner to that of Example 1 (3). m.p. 248°C (dec.) (Recrystallization from dimethylformamide)

I.R. (nujol): 2575, 2475, 1710, 1655 (shoulder), 1645, 1610 cm^{-1}

35 (4) Sodium salt of 1,6-dihydro-6-oxo-2-(4-propoxyphenyl)pyrimidine-4-[N-(5-tetrazolyl)]-carboxamide was obtained according to similar manner to that of Example 2 (4). m.p. >300°C.


I.R. (nujol): 3300, 3075, 1720, 1685, 1610 cm^{-1}

N.M.R. ($\text{N}_2\text{OD}+\text{D}_2\text{O}$) δ ppm: 0.90 (3H, t, J=7Hz), 1.60 (2H, m), 3.62 (2H, t, J=6Hz), 6.64 (2H, d, J=8Hz), 6.76 (1H, s), 7.90 (2H, d, J=8Hz)

40 Anal. Calcd for $\text{C}_{15}\text{H}_{14}\text{N}_7\text{O}_3\text{Na}\cdot\frac{1}{2}\text{H}_2\text{O}$: C; 48.39, H; 4.06, N; 26.33
found: C; 48.48, H; 3.90, N; 26.48

Claims

1. Dihydropyrimidine derivatives of the formula.



wherein

45 R^1 is pyridyl, thienyl, or aryl which may bear one or more substituent(s) selected from the group of halogen, hydroxy, nitro, amino, di(lower)alkylamino, lower alkoxy and ar(lower) alkoxy, and pharmaceutically acceptable salts thereof.

2. A compound according to claim 1, in which R^1 is pyridyl, thienyl or phenyl which may bear one or more substituent(s) selected from the group of halogen, hydroxy, nitro, amino, di(lower)alkylamino, lower alkoxy and phenyl(lower)alkoxy.

50 3. A compound according to claim 2, in which R^1 is pyridyl, thienyl, phenyl, halophenyl,

hydroxyphenyl, nitrophenyl, aminophenyl, di(lower)alkylaminophenyl, mono or di(lower)alkoxyphenyl or phenyl(lower)alkoxyphenyl.


4. A compound according to claim 2, in which R¹ is hydroxyphenyl.

5. A compound according to claim 2, which is 1,6-dihydro-6-oxo-2-(4-hydroxyphenyl)pyrimidine-

5 4-[N-(5-tetrazolyl)]carboxamide or a pharmaceutically acceptable salt thereof.


6. A process for preparing a compound of claim 1, which comprises,

a) reacting a compound of the formula:




wherein

10 R¹ is the same as defined above, or its reactive derivative at the carboxy, with a compound of the formula: 10



or its salt to give a compound (I) or its salt; or

b) subjecting a compound of the formula:




15

15

wherein


R¹ is aryl having a protected hydroxy group, or its salt, to catalytic reduction to give a compound of the formula:



20 wherein


R¹ is aryl having a hydroxy group or its salt; or

c) reducing a compound of the formula:



wherein

25 R¹ is aryl having a nitro group or its salt to give a compound of the formula: 25



wherein

R¹ is aryl having an amino group, or its salt.

30 7. A pharmaceutical composition for the treatment of allergic disease in human beings or animals comprising a compound (I) of claim 1 or pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable carrier. 30